Holmium-166;[4-(phosphonatomethyl)-7,10-bis(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid
DOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in the bone marrow. It is an experimental therapy that is being developed by NeoRx Corporation.